Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 16/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096018 | 0.88 | PTGER1 (0.54) | PTGER1CYP2C9CYP3A4 | |
| SCHEMBL14038802 | 0.86 | PTGER1 (0.53) | PTGER1CYP2C9CYP3A4 | |
| SCHEMBL5099680 | 0.82 | PTGER1 (1.00) | PTGER1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL5095894 | 0.79 | PTGER1 (0.81) | PTGER1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL5109876 | 0.79 | PTGER1 (0.93) | PTGER1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL5096132 | 0.78 | PTGER1 (1.00) | PTGER1CYP2C9CYP3A4MRGPRX4 | |
| SCHEMBL4880523 | 0.78 | PTGER1 (1.00) | PTGER1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL4882993 | 0.78 | PTGER1 (1.00) | PTGER1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL7247876 | 0.78 | PTGER4 (0.66) | PTGER1CYP2C9 | |
| SCHEMBL5103391 | 0.78 | PTGER1 (0.86) | PTGER1CYP2C9CYP3A4TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225340-A1 | Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | claimed |
| EP-1742916-A1 | PHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-01-17 | — | — | EP | claimed |
| WO-2005108369-A1 | PHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2005-11-17 | — | — | WO | claimed |
| US-7446222-B2 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20070225340-A1 | Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
| EP-1742916-A1 | PHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108369-A1 | PHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225340-A1 | Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor | PTGER1, PTGER2, PTGDR | PTGER1 1/4885CYP2C9 223/4885CYP3A4 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.